ArticleFrontiers in pharmacology2023

Ginsenosides, potential TMPRSS2 inhibitors, a trade-off between the therapeutic combination for anti-PD-1 immunotherapy and the treatment of COVID-19 infection of LUAD patients.

Mei Meng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.